Sex-linked lymphopenic immunologic deficiency has in the past been invariably fatal. The use of bone marrow transplantation appears to have effected the first known cure of this genetically determined disorder. Perhaps more significantly, the methods used and the lessons learned open a new and intriguing approach to management by cellular therapy of a wide range of “molecular” diseases.